Stem cells cure deadly human skin diseaseFor the first time researchers at universities Bochum (Germany), Salzburg (Austria), and Modena (Italy) have shown that autologous transgenic keratinocyte cultures can regenerate an entire, fully functional … more ➔
InflaRx Announces Pricing of Initial Public Offering German inflammation and autoimmunity specialist InflaRx AG (Jena) announced it will offer 6,667,000 common shares at an Nasdaq initial public offering price of $15.00 per common share, resulting in … more ➔
FDA lifts clinical hold on Cellectis Phase I trialsThe US Food and Drug Administration (FDA) has lifted the clinical hold due to a patient death on Phase I testing of UCART123 in acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm … more ➔
MAB Discovery expands 2013 partnership with BioNTech AG German MAB Discovery GmbH has extended its 2013 collaboration with BioNTech AG by a contract to produce another set of therapeutic antibodies against a range of targets delivered by BioNTec. more ➔
European biotech stocks: New wave of optimismIn 2017, the European biotech sector witnessed a volume increase in IPOs and follow-on financings. This says the most recent capital market report of BIOCOM which is published during BIO-Europe on November … more ➔
NousCom raises €42mSwiss oncolytic virus and vaccine specialist NousCom has closed a €42m Series B financing round led by new investor Abingworth. Co-investors include new 5AM Ventures, and existing investors LSP and … more ➔
Blocking antibody recycling vs autoimmune diseasesResearchers at Belgian UCB SA have clinically demonstrated that an antibody targeting a normal cellular recycling process can remove autoantibodies from the blood of people with autoimmune diseases. … more ➔
Another death related to allogenic CAR-T cell therapyFollowing the death of a patient with blastic plasmacytoid dendritic cell neoplasm (BPDCN), the FDA put a hold on two clinical Phase I trials with UCART123, French Cellectis SA’s allogenic CAR-T therapies. … more ➔
BioGeneration Ventures Fund III closed at €82mDutch venture capital company BioGeneration Ventures (BGV) has closed its third fund, BGV III, at €82m exceeding the original target by €32m. more ➔
Ablynx IPO Ablynx raises US$230mBelgian nanobody producer Ablynx closes an initial public offering of American Depositary Shares at Nasdaq totalling US$200m plus a fully exercised greenshoe option amounting aggregate gross … more ➔
